{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093295","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.016282+00:00","generated_at":"2026-05-31T10:59:10.873077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients","bullets":["Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.","Cash and investments $107.6M as of June 30; expected funding into mid-2026.","Completed enrollment in bempikibart AD Phase 2 trial (121 patients); topline results on track for Q4 2024.","ADX-097 Phase 2 basket trial for renal diseases enrolling; initial open-label data expected by year-end 2024.","Bempikibart AA Phase 2 topline results also expected in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093295","json":"https://secwatch.observer/filing/0000950170-24-093295.json","markdown":"https://secwatch.observer/filing/0000950170-24-093295.md","text":"https://secwatch.observer/filing/0000950170-24-093295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024093295/0000950170-24-093295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017024093295/qttb-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:59:10.873077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}